-
Ofatumumab is a
fully human monoclonal antibody to CD20,
which appears to
provide rapid B-cell depletion.
Under the
brand name Kesimpta, it is approved...
- CD20 protein,
ofatumumab binds to a separate,
small loop. This may
explain their different characteristics.
Compared to rituximab,
ofatumumab induces complement-dependent...
- 22-0.25
Zeposia Ozanimod [better source needed] Oral 0.18-0.24
Kesimpta Ofatumumab Subcutaneous 70% 0.09-0.14
Mavenclad Cladribine Oral 70% 0.1-0.14 Lemtrada...
- developed: ocrelizumab,
humanized (90%-95% human) B cell-depleting agent.
ofatumumab (HuMax-CD20) a
fully human B cell-depleting agent. Third-generation anti-CD20s...
-
GlaxoSmithKline decided to exit oncology,
which impacted co-development of
ofatumumab, an oncology-directed product. In
tandem with the sale of the plant, the...
- this disease,
other anti-CD20
drugs such as ocrelizumab, veltuzumab, and
ofatumumab have been
explored as
potential treatments. Key
companies in Pemphigus...
- CD20 is the
target of the mAbs rituximab, ocrelizumab, obinutuzumab,
ofatumumab,
ibritumomab tiuxetan, tositumomab, and ublituximab,
which are all active...
-
Bevacizumab Cetuximab Dostarlimab Gemtuzumab ozogamicin Ipilimumab Nivolumab Ofatumumab Panitumumab Pembrolizumab Ranibizumab Rituximab Trastuzumab Monoclonal...
-
company acquired the
remaining rights to the CD20
monoclonal antibody Ofatumumab from
GlaxoSmithKline for up to $1 billion. In
October the
company acquired...
-
ibrutinib down-modulates the
expression of CD20 (target of rituximab/
ofatumumab) by
targeting the CXCR4/SDF1 axis. Together,
these data are consistent...
